Economics at your fingertips  

Viability of a New Road Infrastructure with Heterogeneous Users in Madrid Access

Pedro Cantos-Sánchez (), Rafael Moner-Colonques, José Sempere-Monerris () and Óscar Álvarez San-Jaime ()

No 2008-06, Working Papers from FEDEA

Abstract: This paper explores the importance of heterogeneity in value of time when assessing the viability of a new road infrastructure to alleviate congestion problems. The Spanish government has developed a congestion pricing demonstration entering Madrid city centre, where road users have to choose between a free but highly congested road and a priced free-flowing road. We consider a continuum of users who differ in their value of time. Users dislike congestion and this is more so the more a user values his travel time. A logit estimation is undertaken with information from a questionnaire among road users in the Eastern Madrid area to obtain users' value of time. The impact and viability of artery road R3 under several competitive regimes is examined. The tolls obtained generate a traffic reallocation towards the new roadway such that revenues suffice to render the infrastructure socio-economically viable. This is so for all the competitive regimes analyzed even for modest traffic growth rates. Regarding economic viability, the artery road infrastructure is always economically viable under the private regime and for the other two regimes, a sufficiently high traffic growth rate is required.

Date: 2008-01
New Economics Papers: this item is included in nep-ure
References: View references in EconPapers View complete reference list from CitEc
Citations: Track citations by RSS feed

Downloads: (external link) (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link:

Access Statistics for this paper

More papers in Working Papers from FEDEA
Bibliographic data for series maintained by Carmen Arias ().

Page updated 2020-08-06
Handle: RePEc:fda:fdaddt:2008-06